Slingshot members are tracking this event:

FDA Accepts Novartis' (NVS) Supplemental New Drug Application (sNDA) Under Priority Review for Zykadia (Ceritinib) in First-Line Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Supplemental New Drug Application, Snda, Priority Review, Zykadia, Ceritinib, First-line Treatment, Metastatic, Alk-positive, Non-small Cell Lung Cancer, Nsclc